A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes
NCT00351546
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:
Vildagliptin
Sponsor
Novartis